Showing results (201-210 of 248) with videos related to

Sort By:
Pageof 25
American Journal of Human Genetics|January 1, 1991
Identification of a highly polymorphic microsatellite VNTR within the argininosuccinate synthetase locus: exclusion of the dystonia gene on 9q32-34 as the cause of dopa-responsive dystonia in a large kindredD J Kwiatkowski, T G Nygaard, D E Schuback, et al.
Neurology|August 28, 2024
Effect of Ubrogepant on Patient-Reported Outcomes When Administered During the Migraine Prodrome: Results From the Randomized PRODROME TrialRichard B Lipton, Andrea M Harriott, Julia Y Ma, et al.
Scientific Reports|September 14, 2013
Probing the interplay between quantum charge fluctuations and magnetic ordering in LuFe2O4J Lee, S A Trugman, C D Batista, et al.
AIDS and Behavior|June 30, 2019
Perspectives from Young South African and Zimbabwean Women on Attributes of Four (Placebo) Vaginal Microbicide Delivery FormsR Weinrib, E N Browne, M K Shapley-Quinn, et al.
Ophthalmology|June 12, 2014
A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitisSivakumar R Rathinam, Manohar Babu, Radhika Thundikandy, et al.
Therapeutic Advances in Neurological Disorders|January 28, 2025
A multi-country cohort database study to assess pregnancy and infant outcomes after potential maternal or paternal exposure to cladribine tablets in the treatment of multiple sclerosis: the CLEAR study methods and status updateKerstin Hellwig, Melinda Magyari, Thomas M MacDonald, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 1, 1994
Exclusion of the DYT1 locus in a non-Jewish family with early-onset dystoniaS B Bressman, A L Hunt, G A Heiman, et al.
JAMA Network Open|June 8, 2022
Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical TrialRichard B Lipton, Patricia Pozo-Rosich, Andrew M Blumenfeld, et al.
Neurology|June 26, 2024
Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS TrialPeter J Goadsby, Deborah I Friedman, Dagny Holle-Lee, et al.
Headache|November 21, 2024
Safety and tolerability of ubrogepant for the acute treatment of migraine in participants taking atogepant for the preventive treatment of episodic migraine: Results from the TANDEM studyJessica Ailani, Richard B Lipton, Andrew M Blumenfeld, et al.
Pageof 25